Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04590404 · ClinicalTrials.gov registry record · Phase 3
Metabolism Informed Smoking Treatment: The MIST RCT
A Phase 3 study, sponsored by Vanderbilt-Ingram Cancer Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 606
- Enrollment target
NCT04590404: Completed Phase 3 study, sponsored by Vanderbilt-Ingram Cancer Center.
NCT04590404 is a Phase 3 study that has completed, run by Vanderbilt-Ingram Cancer Center. The registered enrollment target is 606 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (22% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04590404, a Phase 3 study, has completed, sponsored by Vanderbilt-Ingram Cancer Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 606 participants
- Enrollment target
Study Summary
This phase 3 randomized controlled trial will test Metabolism-Informed Smoking Treatment (MIST), a precision approach to smoking treatment that biologically tailors medication selection to nicotine metabolism.
Interventions
- DRUG Varenicline
- DRUG Nicotine Replacement Therapy
- BEHAVIORAL Post-discharge automated phone calls (IVR) with option to connect with a tobacco coach.
- OTHER Metabolism Informed Smoking Treatment (Nicotine metabolite ratio (NMR)-based selection of pharmacotherapy)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 606 participants |
| Start Date | 2020-11-17 |
| Est. Completion | 2024-11-22 |
| Phase | Phase 3 |
What the finished NCT04590404 record still lists
NCT04590404 is an interventional study that assigns participants to a tested intervention. The registered 606 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (22% lower).
The record links to 0 conditions, and to 4 interventions - of which Varenicline is the first listed.
NCT04590404 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04590404 about?
NCT04590404 is a clinical study titled "Metabolism Informed Smoking Treatment: The MIST RCT". This phase 3 randomized controlled trial will test Metabolism-Informed Smoking Treatment (MIST), a precision approach to smoking treatment that biologically tailors medication selection to nicotine metabolism.
What is the current status of trial NCT04590404?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 606 participants. The study started on 2020-11-17. Estimated completion is 2024-11-22.
What interventions are being tested in trial NCT04590404?
The interventions under investigation include: Varenicline (DRUG), Nicotine Replacement Therapy (DRUG), Post-discharge automated phone calls (IVR) with option to connect with a tobacco coach. (BEHAVIORAL), Metabolism Informed Smoking Treatment (Nicotine metabolite ratio (NMR)-based selection of pharmacotherapy) (OTHER).
Who is sponsoring clinical trial NCT04590404?
This trial is sponsored by Vanderbilt-Ingram Cancer Center, which has 189 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04590404's enrollment target sits among peer trials
606 606th of 2000 higher than 1,394 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02342444 · 606 participants · Phase 4
Lovenox 30 mg Twice Daily (BID) Versus 40 mg Once Daily (QD)
- NCT02064673 · 608 participants · Phase 3
Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy
- NCT06091202 · 608 participants · Phase 3
Tele-Collaborative Outreach to Rural Patients With Chronic Pain
- NCT06098144 · 608 participants · Phase 4
Smoking Cessation Program in the Construction Sector
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI